Family Medicine Doctors in Richland Hills, TX Accepting Medicare
9 Family Medicine doctors found. Showing 1 - 9
 Dr. Ronnie Erwin, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 |
Dr. James Allen, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 |
Dr. Mark Byarlay, Family Medicine Medicare: Medicare Enrolled Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 |
 Dr. Sana Fatima Muntajibuddin, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 Fax: 817-284-3921 |
Sunitha Malla, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 Fax: 817-595-2096 |
Mary Elizabeth Schultzman, FNP-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 8208 Bedford Euless Rd, Richland Hills, TX 76180 Phone: 972-288-9747 Fax: 972-288-2610 |
Dr. Dick Pafford, Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 |
Myungseok Rick Seo, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 |
Dr. Hieu Vu, Family Medicine Medicare: Medicare Enrolled Practice Location: 7601 Glenview Dr, Richland Hills, TX 76180 Phone: 817-274-2578 Fax: 817-284-1430 |
News Archive
New website for PricewaterhouseCoopers' Health Industries practice
PricewaterhouseCoopers LLP today launched a new website for their Health Industries practice – www.pwc.com/healthreform – which will serve as a central point of access for PricewaterhouseCoopers' latest insight and analysis on the implications of health reform for health organizations including insurers, physicians, hospitals and other providers, pharmaceutical and life sciences companies and employers.
Ignyta reports preliminary results from ongoing Phase 1 clinical trial of RXDX-101
Ignyta, Inc., an oncology precision medicine biotechnology company, announced today that Justin Gainor, M.D., of the Massachusetts General Hospital Cancer Center, presented preliminary results from the ongoing Phase 1 dose escalation portion of a Phase 1/2 clinical trial of RXDX-101, Ignyta's proprietary oral tyrosine kinase inhibitor targeting solid tumor indications, at the International Association for the Study of Lung Cancer 14th Annual Targeted Therapies for the Treatment of Lung Cancer Meeting.
New understanding of exaggerated mucous production and secretion in cystic fibrosis
A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice.
Newly developed light-sensing protein restores vision in blind mice
A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy.
› Verified 4 days ago
Family Medicine
Pediatrics
Internal Medicine
Obstetrics & Gynecology